AUTHORS
Kunho Chung, PhD, Dongxu Jiang, PhD2, Christopher Petucci, PhD3, Xiaorong Gu, PhD4, Jessica Kerr, MSc Immunology5, Beatriz Coutinho De Oliveira, PhD6, Meraj Khan, PhD7, Benjamin Kovacic, MS8, Shikha Parsai, MS9, Valdmir Makarov, MD, MS10, Babal Kant Jha, PhD11, J. Joseph Joseph Melenhorst, PhD12
AFFILIATIONS
1 Cleveland Clinic, Cleveland, Ohio, United States
2 Cleveland Clinic, Cleveland, Ohio, United States
3 University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Cleveland Clinic, Cleveland, Ohio, United States
8 Cleveland Clinic, Cleveland, Ohio, United States
9 Cleveland Clinic, Cleveland, Ohio, United States
10 Cleveland Clinic, Cleveland, Ohio, United States
11 Cleveland Clinic, Cleveland, Ohio, United States
12 Cleveland Clinic, Cleveland, Ohio, United States
ABSTRACT
Chimeric antigen receptor (CAR) T cell efficacy in B cell malignancies is limited in a subset of patients by inadequate persistence and progressive dysfunction under chronic antigen exposure. Less-differentiated, central memory–like states are associated with improved expansion and persistence, and TET2 is an α-ketoglutarate (αKG)–dependent DNA dioxygenase that catalyzes cytosine demethylation in the promoter, silencer region in our genome. This process is critical for efficient transcriptional profile that determine cell lineage differentiation, proliferation and survival. In T cell TET2 has been linked with the fitness of cytotoxic long-lived memory T cells. We have demonstrated that TET2 disruption in a clinical CTL019 responder drove clonal expansion of central memory CD8+ CAR T cells, and experimental TET2 loss recapitulated antigen-dependent outgrowth. Because T cell fate is shaped by metabolic–epigenetic programs, we tested whether metabolic rather than genetic inhibition of αKG-dependent dioxygenases could bias CAR T cells toward a memory-like state without inducing oncogenic hyperproliferation. The IDH1 R132H neomorph (IDH1NM) converts αKG to D-2-hydroxyglutarate (D-2HG), a competitive inhibitor of TET enzymes and certain histone lysine demethylases, including the KDM family of lysine demethylases.
We engineered second-generation CD19 CAR T cells with a 4-1BB signaling domain co-expressing IDH1 wildtype (IDH1WT) or IDH1NM from normal donors, manufactured over a 12-day expansion with IL-7 and IL-15, and confirmed IDH1NM expression by western blot and intracellular D-2HG accumulation by mass spectrometry. We profiled transcriptomes (RNA-seq/GSEA), global 5hmC and histone methylation, cytotoxicity against NALM-6, and phenotype and cytokines, using serial restimulation with CD19+ artificial APCs to model chronic antigen exposure and an HPRT assay to test mutagenicity. Despite a slightly lower transduction efficiency, IDH1NM CAR T cells accumulated D-2HG but did not increase population doubling during manufacturing, indicating no oncogenic hyperproliferation, and preserved cytotoxicity against CD19+ NALM-6 targets. Transcriptomic analysis revealed enrichment of memory gene signatures and suppression of effector signatures, with GSEA showing positive enrichment of NOTCH and WNT/β-catenin signaling and negative enrichment of IFN-γ response, inflammatory response, glycolysis, oxidative phosphorylation, hypoxia, mTORC1, and MYC/E2F/G2M proliferation programs. Rather than global suppression of effector function, short-term stimulation revealed a distinct pattern of increased perforin and decreased granzyme A in CD8+ cells and decreased CD107a degranulation with increased CD40L in CD4+ cells. In a serial restimulation model using CD19+ artificial APCs, IDH1NM CAR T cells exhibited enhanced CAR-dependent outgrowth across total, CD4+, and CD8+ compartments, which is an advantage that remained strictly CAR-dependent, as cells did not survive antigen withdrawal, together with increased CCR7+CD45RA− central memory subsets in CD4+ and CD8+ cells, higher CD28 and Ki67 in CD8+ cells, reduced IFN-γ and TNF-α with increased IL-2, and reduced inhibitory receptors (PD-1, Tim-3, TIGIT) on CD8+ cells. Under chronic stimulation, IDH1NM CAR T cells displayed decreased 5hmC, consistent with impaired cytosine oxidation (31.68% decreased to IDH1WT), together with increased H3K4me3 (119% increased to IDH1WT) and H3K9me2 (36.6% increased to IDH1WT) and decreased H3K36me3 (71.4% decreased to IDH1WT), whereas no significant differences were detected in unstimulated cells, and the HPRT assay showed no increase in mutation frequency under genotoxic stress over 15 days under in vitro conditions.
These data support metabolic–epigenetic engineering via the IDH1NM–D-2HG axis to enhance memory programs and persistence in CAR T cells while preserving cytotoxicity and avoiding CAR-independent hyperproliferation; the resulting phenotype is reminiscent of TET2-hypomorphic CAR T cells but arises from a tunable, non-deletional metabolic mechanism, with effector outputs distinct from those of direct TET2 disruption, warranting in vivo evaluation of persistence, antitumor efficacy, and long-term safety; because D-2HG is diffusible, potential paracrine effects on bystander immune and stromal compartments will also require assessment.
DISCLOSURES
J. Joseph Joseph Melenhorst, PhD: No relevant conflicts of interest to declare.